RTP Mobile Logo
Hematologic Oncology Update, Issue 2, 2010
Released May 2010

Featuring interviews with Drs John P Leonard, David P Steensma, Anas Younes and Paul G Richardson. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Over 45 pharmaceutical agents with more than 55 distinct FDA-approved indications are currently available for the management of the numerous types of hematologic cancer. This extensive armamentarium of treatment options poses a challenge to clinicians who must maintain up-to-date knowledge of optimal therapeutic algorithms for diverse tumor types. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading oncology investigators. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of state-of-the-art clinical management strategies, which in turn facilitates optimal patient care.

    LEARNING OBJECTIVES

    • Apply emerging research results to effectively and safely integrate novel agents and regimens into the initial management of follicular lymphoma.
    • Recall the emerging subtypes of diffuse large B-cell lymphoma and their implications for personalized therapy.
    • Formulate optimal front-line and maintenance strategies for patients with acute promyelocytic leukemia.
    • Describe the standard therapeutic approaches and investigational strategies for the treatment of newly diagnosed and relapsed Hodgkin lymphoma.
    • Identify patients at high risk for tumor lysis syndrome (TLS), and incorporate recent research data into the prevention and management of TLS.
    • Integrate innovative combination regimens into the management of multiple myeloma (MM), considering the benefits and risks of proteasome inhibitors and immunomodulatory agents.
    • Evaluate consolidation and maintenance therapy approaches for patients with MM.
    • Counsel appropriately selected patients about the availability of ongoing clinical trials in which they may be eligible to participate.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains both audio and print components. To receive credit, the participant should listen to the audio MP3s, read the text portion and complete the Post-test and Educational Assessment and Credit Form located on our website at CME.ResearchToPractice.com. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
     
    FACULTYDr Steensma had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr LeonardConsulting Agreements: Biogen Idec, Biotest Pharmaceuticals Corporation, Calistoga Pharmaceuticals Inc, Celgene Corporation, Cephalon Inc, CT International, Eisai Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Gloucester Pharmaceuticals, Immunomedics Inc, Intellikine, Johnson & Johnson Pharmaceuticals, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis, Wyeth. Dr YounesAdvisory Committee and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Pharmion Corporation, Roche Laboratories Inc, Sanofi-Aventis. Dr RichardsonAdvisory Committee: Celgene Corporation, Millennium Pharmaceuticals Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS
    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
     

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Allos Therapeutics, Celgene Corporation, Cephalon Inc, Genentech BioOncology/Biogen Idec, Millennium Pharmaceuticals Inc, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2010
    Expiration date: May 2011

     

Acknowledge and close

Hematologic Oncology Update, Issue 2, 2010
Released May 2010

Featuring interviews with Drs John P Leonard, David P Steensma, Anas Younes and Paul G Richardson. (Text and Audio Content)